CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 178 target
Drug / intervention
LBL-024 for Injection +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06157827
NCT06157827Phase 2RecruitingOn TrackUpdated 3mo ago
CompareCT.gov

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)

Nanjing Leads Biolabs Co.,Ltd·interventional·Posted Dec 6, 2023·Updated Mar 12, 2026

In Brief

A Phase 2 clinical trial evaluating LBL-024 for Injection, Etoposide Injection, and 3 other interventions for Advanced Neuroendocrine Carcinoma. Currently recruiting, targeting 178 participants across 25 sites.

Detailed Summary

An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Neuroendocrine Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
2024202520262027
First PostedDec 6, 2023
Enrollment StartDec 8, 2023
Primary CompletionDec 28, 2026
Study CompletionMar 28, 2027
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 2.6 years agoPrimary completion in 6 months

Interventions

LBL-024 for Injectiondrug

intravenous infusion

Etoposide Injectiondrug

intravenous infusion

Carboplatin Injectiondrug

intravenous infusion

Atezolizumab injectiondrug

intravenous infusion

Cisplatin injectiondrug

intravenous infusion